Scott Edelman, CEO

Mr. Edelman is responsible for the growth and financial health of the company. With over 30 years’ experience with pre-clinical CRO services, tissue processing, biorepository banking, and numerous application software firms, Mr. Edelman enjoys partnering with scientific entrepreneurs to achieve their scientific, business, and financial goals. Prior to Radix, Mr. Edelman was one of the founders and CEO of a cell-based CRO providing innovative hepatic products and services to expedite the development of safe and effective drugs. Mr. Edelman was also one of the founders and CEO of an adipose tissue processing and biobanking start-up, the CEO of a collaborative decision-making software tools company, and served as the chief operating executive of numerous enterprise application software firms with domestic and international operations.

Kerry Oliver, Ph.D., President & CSO

Dr. Oliver currently serves as the President and Chief Scientific Officer of Radix and, as such, sets the scientific strategy for the company.  He has spent his career chemically modifying reagents for use in developing immunoassays.  Over the last 10 years, Dr. Oliver has implemented the use of DOE to optimize reagent modifications and immunoassay performance.  Prior to founding Radix, Dr. Oliver was involved with research and commercialization efforts in pharmaceutical companies, medical device startups, academia, and government labs.

Cari McDonald, Director of Assay Development

Ms. McDonald has over 25 years of assay development experience, including 12 years at Radix.  She began her assay development and sample testing experience in the animal pharmaceutical industry and then moved to human health at Mayo Clinic. At Radix, Ms. McDonald is using her experience to support both animal and human health.  She has expanded her skills to include critical reagent labeling as well as kit manufacturing and validation.

Van Fitzgerald, MS, Director of Manufacturing

Mr. Fitzgerald has accrued over 25 years of experience in the biotechnology and medical device industries, including roles in research, assay development, product/process development, quality control and reagent manufacturing.  At Radix, Mr. Fitzgerald focuses on assay development, sample testing and protein modification/purification.


Félix W. Santiago, Ph.D., Director of Assay Services

Dr. Santiago has over 15 years of combined research experience in immunology and immunoassay assay development.  He currently leads the day-to-day operations of the company’s sample testing/bioanalytical services. Over the last 10 years, Dr. Santiago has provided pre-clinical and clinical sample screening and testing services for partners in the academia and pharmaceutical industry sectors. Additionally, during this time, he has been involved in the development, optimization, and manufacturing of immune assays for the detection of human cytokines and chemokines, C. difficile toxins, avian influenza viral proteins, and Zika viral proteins among others.

Christopher Muñoz, MS, Senior Chemist

Mr. Muñoz joined Radix in 2018 to develop de-novo reagent conjugation methods. During his time at Radix he has been involved in the development, optimization, and characterization of bioconjugation techniques for proteins that exhibit poor recovery or inconsistent labeling behavior. His methods have been successfully implemented for critical reagent labeling and immunoassay development. Additionally, Mr. Muñoz currently assists in the day-to-day operations of the company’s sample testing/bioanalytical services.

Janet Janssen, Director of Finance & Accounting

Ms. Janssen is a certified public accountant with over 20 years of accounting experience. After initially starting in public accounting, she changed her focus in 2003 to working with growing companies ranging from biotechnology firms to e-commerce businesses. Ms. Janssen joined Radix in early 2012 and is responsible for the day-to-day financial and accounting operations of the company.